Beta Drugs Peer Comparison

NSE: BETA

₹1,976.80

₹42.60 (2.20%)

As on 28-Oct-2026IST

Market cap

₹2,198 Cr

Revenue (TTM)

₹444 Cr

P/E Ratio

42.3

P/B Ratio

Div. Yield

0 %

Edit

	Beta Drugs	Acutaas Chemicals	Piramal Pharma	Onesource Specialty Pharma	Syngene Intl
Market cap (₹ Cr)	2,198	30,346	30,994	18,044	16,619
Revenue (₹ Cr)	444	1,593	9,779	1,684	3,522
Net Profit (₹ Cr)	53.34	438.64	-270.51	-1.62	186.10
Net Margin (%)	11.78	27.16	-2.71	-0.10	5.15
RoE (%)	15.21	25.02	-2.55	0.22	4.93
Price to Earnings	42.34	69.10	--	--	89.30
Price-To-Book	5.02	16.34	3.81	3.05	3.42

Income Statement (₹ Cr)

	Beta Drugs	Acutaas Chemicals	Piramal Pharma	Onesource Specialty Pharma	Syngene Intl
Operating Revenue	444.27	1,592.52	9,778.62	1,683.82	3,522.30
Total Income	452.81	1,615.23	9,993.26	1,695.30	3,613.20
Total Expenditure	351.96	969.32	8,578.44	1,287.94	2,771.50
EBITDA	92.31	623.20	1,200.18	395.88	750.80
Depreciation	18.14	41.96	887.82	288.26	449.10
EBIT	74.17	581.24	312.36	107.62	301.70
Interest	12.58	4.21	347.94	126.12	43.60
Other Income	8.54	22.71	214.64	11.47	90.90
Exceptional Items	0.00	0.00	-216.88	-13.12	-96.80
Profit before Tax	70.12	599.74	-37.82	-20.14	252.20
Provision for Tax	16.79	161.10	232.69	-18.52	66.10
Profit after Tax	53.34	438.64	-270.51	-1.62	186.10

	Beta Drugs	Acutaas Chemicals	Piramal Pharma	Onesource Specialty Pharma	Syngene Intl
Shareholder's Funds	437.70	1,857.45	8,142.24	5,920.89	4,858.80
Minority Interest	-1.42	0.51	0.55	0.00	0.00
Non-Current Liabilities	37.20	47.15	5,213.99	1,001.58	616.80
Current Liabilities	144.38	253.37	5,158.51	1,663.61	1,182.90
Total Liabilities	503.72	1,983.96	17,723.32	8,222.05	7,054.70

	Beta Drugs	Acutaas Chemicals	Piramal Pharma	Onesource Specialty Pharma	Syngene Intl
Non-Current Assets	232.30	1,132.12	10,687.30	6,364.60	3,950.40
Current Assets	379.62	1,012.00	7,253.65	1,697.49	1,948.10
Total Assets	503.72	1,983.96	17,723.32	8,222.05	7,054.70
Total Debt*	147.81	26.49	5,495.48	1,276.30	9.40
Net Current Assets	235.24	758.64	2,095.14	33.87	765.20
Contingent Liabilities	--	17.25	95.72	1,287.25	536.50

	Beta Drugs	Acutaas Chemicals	Piramal Pharma	Onesource Specialty Pharma	Syngene Intl
Cash From Operating Activities	37.29	292.17	1,652.60	8.52	915.20
Cash Flow from Investing Activities	-51.39	-265.94	-826.03	-494.98	-860.40
Cash from Financing Activities	-8.07	4.10	-38.98	359.44	-215.00
Net Cash Inflow / Outflow	-22.18	30.33	787.59	-127.02	-160.20

	Beta Drugs	Acutaas Chemicals	Piramal Pharma	Onesource Specialty Pharma	Syngene Intl
ROCE (%)	19.16	32.42	1.24	0.44	9.48
ROE (%)	15.21	25.02	-2.55	0.22	4.93
ROA (%)	16.25	22.40	-1.56	-0.02	2.82
EBIT Margin (%)	16.69	36.50	3.19	6.39	8.57
Net Margin (%)	11.78	27.16	-2.71	-0.10	5.15
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Beta Drugs	Acutaas Chemicals	Piramal Pharma	Onesource Specialty Pharma	Syngene Intl
Revenue Growth (%)	15.20	45.18	9.43	10.66	-5.99
EBIT Growth (%)	19.55	115.51	-3.72	-55.98	-48.77
Net Profit Growth (%)	27.30	95.80	-199.34	-103.99	-60.25
EPS Growth (%)	6.38	63.29	-410.28	-91.16	-49.04
Book Value Growth (%)	24.19	26.03	0.33	-0.75	2.11

	Beta Drugs	Acutaas Chemicals	Piramal Pharma	Onesource Specialty Pharma	Syngene Intl
Price / Earnings	40.93	69.10	-149.04	1,407.04	69.48
Price / Book Value	5.02	16.34	3.81	3.05	3.42
Dividend Yield (%)	0.00	0.07	0.00	0.00	0.30
EV/EBITDA	24.06	48.37	29.27	48.54	20.43
Market Cap (₹ Cr)	1,205.58	20,944.75	18,108.89	16,876.12	15,723.10

	Beta Drugs	Acutaas Chemicals	Piramal Pharma	Onesource Specialty Pharma	Syngene Intl
Debt to Equity	0.06	0.02	0.55	0.10	0.00
Short term debt to equity ratio	0.03	0.00	0.09	0.10	0.00
Current Ratio	2.63	3.99	1.41	1.02	1.65
Quick Ratio	2.06	2.89	0.77	0.75	1.51
Interest Coverage	6.57	143.52	0.89	0.84	6.78

	Beta Drugs	Acutaas Chemicals	Piramal Pharma	Onesource Specialty Pharma	Syngene Intl
Debtors to sales (%)	37.69	22.50	23.05	61.34	10.94
Asset Turnover	1.35	0.81	0.56	0.20	0.53
Receivable days	105.14	88.98	78.20	140.79	50.33
Inventory Days	63.66	56.04	93.30	75.94	14.43
Payable days	161.92	99.95	226.14	225.76	17,487.50
Cash Conversion Cycle	6.88	45.07	-54.64	-9.03	-17,422.74

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.